Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Myelodysplastic Syndromes: ESMO Clinical Practice Guidelines

Published in 2014 – Ann Oncol (2014) 25 (suppl 3): iii57-iii69.
Authors: P. Fenaux, D. Haase, G. F. Sanz, V. Santini, C. Buske

Myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell (HSC) disorders predominating in the elderly, with a median age at diagnosis of ~70 years. The aetiology of MDS is known in only 15% of cases. The first clinical practice guidelines from ESMO cover the diagnosis and management of these rare syndromes and also include information on cytomorphology, cytogenetics, prognosis and risk assessment and supportive care.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings